Contractility defects hinder glycoprotein VI-mediated platelet activation and affect platelet functions beyond clot contraction.

blebbistatin hemostasis nonmuscle myosin type IIA thrombosis traction

Journal

Research and practice in thrombosis and haemostasis
ISSN: 2475-0379
Titre abrégé: Res Pract Thromb Haemost
Pays: United States
ID NLM: 101703775

Informations de publication

Date de publication:
Jan 2024
Historique:
received: 22 07 2023
revised: 23 12 2023
accepted: 03 01 2024
medline: 21 2 2024
pubmed: 21 2 2024
entrez: 21 2 2024
Statut: epublish

Résumé

Active and passive biomechanical properties of platelets contribute substantially to thrombus formation. Actomyosin contractility drives clot contraction required for stabilizing the hemostatic plug. Impaired contractility results in bleeding but is difficult to detect using platelet function tests. To determine how diminished myosin activity affects platelet functions, including and beyond clot contraction. Using the myosin IIA-specific pharmacologic inhibitor blebbistatin, we modulated myosin activity in platelets from healthy donors and systematically characterized platelet responses at various levels of inhibition by interrogating distinct platelet functions at each stage of thrombus formation using a range of complementary assays. Partial myosin IIA inhibition neither affected platelet von Willebrand factor interactions under arterial shear nor platelet spreading and cytoskeletal rearrangements on fibrinogen. However, it impacted stress fiber formation and the nanoarchitecture of cell-matrix adhesions, drastically reducing and limiting traction forces. Higher blebbistatin concentrations impaired platelet adhesion under flow, altered mechanosensing at lamellipodia edges, and eliminated traction forces without affecting platelet spreading, α-granule secretion, or procoagulant platelet formation. Unexpectedly, myosin IIA inhibition reduced calcium influx, dense granule secretion, and platelet aggregation downstream of glycoprotein (GP)VI and limited the redistribution of GPVI on the cell membrane, whereas aggregation induced by adenosine diphosphate or arachidonic acid was unaffected. Our findings highlight the importance of both active contractile and passive crosslinking roles of myosin IIA in the platelet cytoskeleton. They support the hypothesis that highly contractile platelets are needed for hemostasis and further suggest a supportive role for myosin IIA in GPVI signaling.

Sections du résumé

Background UNASSIGNED
Active and passive biomechanical properties of platelets contribute substantially to thrombus formation. Actomyosin contractility drives clot contraction required for stabilizing the hemostatic plug. Impaired contractility results in bleeding but is difficult to detect using platelet function tests.
Objectives UNASSIGNED
To determine how diminished myosin activity affects platelet functions, including and beyond clot contraction.
Methods UNASSIGNED
Using the myosin IIA-specific pharmacologic inhibitor blebbistatin, we modulated myosin activity in platelets from healthy donors and systematically characterized platelet responses at various levels of inhibition by interrogating distinct platelet functions at each stage of thrombus formation using a range of complementary assays.
Results UNASSIGNED
Partial myosin IIA inhibition neither affected platelet von Willebrand factor interactions under arterial shear nor platelet spreading and cytoskeletal rearrangements on fibrinogen. However, it impacted stress fiber formation and the nanoarchitecture of cell-matrix adhesions, drastically reducing and limiting traction forces. Higher blebbistatin concentrations impaired platelet adhesion under flow, altered mechanosensing at lamellipodia edges, and eliminated traction forces without affecting platelet spreading, α-granule secretion, or procoagulant platelet formation. Unexpectedly, myosin IIA inhibition reduced calcium influx, dense granule secretion, and platelet aggregation downstream of glycoprotein (GP)VI and limited the redistribution of GPVI on the cell membrane, whereas aggregation induced by adenosine diphosphate or arachidonic acid was unaffected.
Conclusion UNASSIGNED
Our findings highlight the importance of both active contractile and passive crosslinking roles of myosin IIA in the platelet cytoskeleton. They support the hypothesis that highly contractile platelets are needed for hemostasis and further suggest a supportive role for myosin IIA in GPVI signaling.

Identifiants

pubmed: 38379711
doi: 10.1016/j.rpth.2024.102322
pii: S2475-0379(24)00008-6
pmc: PMC10877441
doi:

Types de publication

Journal Article

Langues

eng

Pagination

102322

Informations de copyright

© 2024 The Author(s).

Auteurs

Martin Kenny (M)

School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland.
Irish Centre for Vascular Biology, Royal College of Surgeons in Ireland, Dublin, Ireland.

Alice Y Pollitt (AY)

School of Biological Sciences, University of Reading, Reading, United Kingdom.

Smita Patil (S)

School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland.
Irish Centre for Vascular Biology, Royal College of Surgeons in Ireland, Dublin, Ireland.

Dishon W Hiebner (DW)

School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland.
Irish Centre for Vascular Biology, Royal College of Surgeons in Ireland, Dublin, Ireland.

Albert Smolenski (A)

School of Medicine, Conway Institute, University College Dublin, Belfield, Dublin, Ireland.

Natalija Lakic (N)

School of Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland.

Robert Fisher (R)

School of Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland.

Reema Alsufyani (R)

School of Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland.

Sebastian Lickert (S)

Department of Health Sciences and Technologies, ETH Zurich, Zurich, Switzerland.

Viola Vogel (V)

Department of Health Sciences and Technologies, ETH Zurich, Zurich, Switzerland.

Ingmar Schoen (I)

School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland.
Irish Centre for Vascular Biology, Royal College of Surgeons in Ireland, Dublin, Ireland.

Classifications MeSH